FATE THERAPEUTICS INC Amortization of Debt Discount (Premium)
FATE THERAPEUTICS INC (FATE) reported Amortization of Debt Discount (Premium) of $24.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2015-03-12
- FATE THERAPEUTICS INC amortization of debt discount (premium) for the quarter ending 2014-12-31 was $7.00K, a 97.36% decline year-over-year.
- FATE THERAPEUTICS INC amortization of debt discount (premium) for the quarter ending 2014-09-30 was $3.00K, a 96.81% decline year-over-year.
- FATE THERAPEUTICS INC amortization of debt discount (premium) for the quarter ending 2014-06-30 was $6.00K, a 64.71% decline year-over-year.
- FATE THERAPEUTICS INC amortization of debt discount (premium) for the quarter ending 2014-03-31 was $8.00K, a 55.56% decline year-over-year.
- FATE THERAPEUTICS INC amortization of debt discount (premium) for fiscal 2014 was $24.00K, a 93.91% decline from fiscal 2013.
- FATE THERAPEUTICS INC amortization of debt discount (premium) for fiscal 2013 was $394.00K, a 369.05% increase from fiscal 2012.
- FATE THERAPEUTICS INC amortization of debt discount (premium) for fiscal 2012 was $84.00K, a 265.22% increase from fiscal 2011.
- FATE THERAPEUTICS INC amortization of debt discount (premium) for fiscal 2011 was $23.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 77 month | Amortization of Debt Discount (Premium) 80 month | Amortization of Debt Discount (Premium) 83 month |
|---|---|---|---|---|---|---|---|
| 2014-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $10.00K derived: sum of 2 quarters · filed 2015-03-12 | $16.00K derived: sum of 3 quarters · filed 2015-03-12 | $24.00K 10-K · filed 2015-03-12 | |||
| 2014-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $9.00K derived: sum of 2 quarters · filed 2014-11-12 | $17.00K 10-Q · filed 2014-11-12 | $282.00K derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2014-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $14.00K 10-Q · filed 2014-08-12 | $279.00K derived: sum of 3 quarters · filed 2015-03-12 | $373.00K derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2014-03-31 | $8.00K 10-Q · filed 2014-05-13 | $273.00K derived: sum of 2 quarters · filed 2015-03-12 | $367.00K derived: sum of 3 quarters · filed 2015-03-12 | $384.00K derived: sum of 4 quarters · filed 2015-03-12 | $543.00K 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $359.00K derived: sum of 2 quarters · filed 2015-03-12 | $376.00K derived: sum of 3 quarters · filed 2015-03-12 | $394.00K 10-K · filed 2015-03-12 | $535.00K 10-K · filed 2014-03-17 | ||
| 2013-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $111.00K derived: sum of 2 quarters · filed 2014-11-12 | $129.00K 10-Q · filed 2014-11-12 | $150.00K derived: sum of 4 quarters · filed 2015-03-12 | $271.00K 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $35.00K 10-Q · filed 2014-08-12 | $56.00K derived: sum of 3 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $18.00K 10-Q · filed 2014-05-13 | $39.00K derived: sum of 2 quarters · filed 2015-03-12 | |||||
| 2012-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $84.00K 10-K · filed 2015-03-12 | |||||
| 2012-09-30 | $63.00K 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | $23.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |